Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
By: Jackie Perodin In 2015, the Ministry of Health (MOH) of the Republic of Guinea and the National Institute of Allergy and Infectious Diseases (NIAID) signed a Memorandum of Understanding (MOU) for Cooperation in Biomedical Research. Under the MOU, involved parties conducted collaborative clinical research on the Ebola virus and other infectious diseases, including the
Read more
By: Adhella Menur 2017-2018 2022-2023 On July 23, 2022, the WHO declared the Mpox outbreak a Public Health Emergency of International Concern (PHEIC) – ended in May 2023. In November 2022, the WHO renamed Monkeypox to Mpox to avoid misperception, racist, and discriminatory connotations. 2023 – ongoing M for “Meet” the virus Ia -> classic
Read more
By: Adhella Menur, Lidya Chaidir If you read last year’s newsletter about the 7th Re-PORT Annual Meeting in Goa, India (INA-RESPOND Newsletter Sept 2023), we now bring you an update on the 8th RePORT Annual Meeting held in Salvador, Brazil. To refresh your memory, RePORT (Regional Prospective Observational Research in Tuberculosis (TB)) is an international
Read more
By: Chris Worthington, Caeul Lim, Jestina Doe-Anderson Imagine a world where everything is done right. There would be little room for demonstration of integrity. We don’t live in that kind of world. In our world, things that were once done wrong can be done right; things that could be done wrong can be avoided; and
Read moreBy: Ni Luh Putu Ariastuti, Adhella Menur CHIKV: The neglected bending virus Chikungunya virus (CHIKV) infection might not be as famous as dengue virus (DENV) or Zika virus (ZIKV) infection due to the low mortality rate compared to other infections. But don’t let that fool you; its high morbidity rate and long-lasting health issues create
Read moreBy: Edrick Purnomo Putra Walking is a form of physical activity that can be easily done by most people. It is a part of our daily life and does not require specific equipment or a special environment. Walking has become popular as a form of physical activity to gain health benefits, even leading to the
Read moreBy: Aly Diana In the realm of public health and development, ensuring the quality and effectiveness of interventions is paramount. Lot Quality Assurance Sampling (LQAS) is a powerful yet straightforward tool that offers a robust method for assessing quality and coverage in various programs. Originally developed in the manufacturing industry, LQAS has been adapted for
Read moreBy: Katy Shaw-Saliba Measles virus (MeV) is one of the most contagious infectious agents; thus, despite having a highly safe and effective vaccine available, sustained high vaccine coverage (>90%) is required to interrupt transmission [1]. Infection with MeV is diagnosed clinically by the presence of a characteristic fever and maculopapular rash, potentially accompanied by coryza,
Read moreBy: Adhella Menur Watching the record of Prof. dr. Bachti Alisjahbana, Sp.PD-KPTI, Ph.D.’s scientific oration and reading Gustiani’s report of her TB biomarker laboratory training in Brazil brought me back to my time as a Research Assistant (RA) for the TRIPOD study (Tuberculosis Research of INA-RESPOND on Drug Resistance). In 2017, I transitioned from working
Read moreTo collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
